Oxaliplatin Fresenius Kabi (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic agent that interferes with DNA replication in malignant cells.

• Colorectal cancer: used in combination regimens to shrink tumor size and improve survival rates.
• Gastric cancer: employed as part of multi‑drug protocols to control disease progression.
• Pancreatic cancer: incorporated in combination therapy to enhance treatment response.
• Ovarian cancer: used alongside other agents to target resistant disease.
• Small‑cell lung cancer: added to regimens for patients who have limited options.
• Metastatic disease: applied in various solid‑tumor protocols where platinum sensitivity is demonstrated.

• Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑ and inter‑strand cross‑links, disrupting DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells while sparing most normal tissues.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhea: loose stools that may require supportive care.
• Fatigue: generalized tiredness affecting daily activities.
• Thrombocytopenia: reduced platelet count increasing bleed risk.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention.
• Acute hemolytic anemia: rapid destruction of red blood cells.
• Pulmonary toxicity: interstitial lung disease or pneumonitis.
• Renal impairment: acute kidney injury, especially with dehydration.
• Cardiotoxicity: arrhythmias or myocardial ischemia in susceptible patients.
• Secondary malignancies: rare risk of therapy‑related cancers.

When handling Oxaliplatin, clinicians should consider several safety measures to protect patients and staff.

• Renal function monitoring: assess creatinine clearance before each cycle.
• Hepatic function monitoring: check liver enzymes regularly.
• Neuropathy assessment: evaluate sensory changes at each visit.
• Hematologic monitoring: perform complete blood counts to detect cytopenias.
• Hydration status: ensure adequate fluid intake to reduce renal toxicity.
• Store at below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage.
• Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely)

• Antiemetics (e.g., ondansetron): may require dose adjustment for optimal control of nausea.
• CYP450 inducers (e.g., rifampicin): potential reduction in drug exposure.
• Radiotherapy: may amplify peripheral neuropathy.
• High‑dose vitamin C: theoretical reduction in platinum‑DNA binding.
• NSAIDs: possible additive effect on platelet dysfunction.